# Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

> **NCT07285057** · PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 120 (estimated)

## Conditions studied

- Prostatic Neoplasms
- Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

- **RADIATION:** rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®)
- **DRUG:** Flotufolastat F18

## Key facts

- **NCT ID:** NCT07285057
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285057, "Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07285057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*